Head to head
CoQ10 against Idebenone
A supplement and a synthetic analogue of it that became a medicine in one rare disease. Idebenone was authorised in the European Union under exceptional circumstances because the normal evidence standard was not met, and its trial missed its primary endpoint.
Column A
CoQ10Coenzyme Q10 (ubiquinone and ubiquinol)
One genuinely strong randomised outcome trial, in moderate to severe heart failure, where it cut major events from 26% to 15%. And a clean null for statin muscle pain, which is why most people take it.
Column B
IdebenoneIdebenone, short-chain synthetic benzoquinone analogue of coenzyme Q10
Authorised in the European Union for one rare mitochondrial optic neuropathy, granted under exceptional circumstances because the normal evidence standard was not met. The randomised trial that supported it missed its primary endpoint, and the trials in Alzheimer's disease and Friedreich ataxia were negative.
Side by side, on the facts we can check
| Attribute | CoQ10 | Idebenone |
|---|---|---|
| Category | Antioxidant | Antioxidant |
| FDA status | Sold as a dietary supplement in the United States. Not approved to prevent or treat any condition. Approved as a drug in some other jurisdictions for specific cardiac indications. | Not FDA approved for any indication. Authorised in the European Union as Raxone for Leber hereditary optic neuropathy since September 2015, under exceptional circumstances. Separately sold in topical skincare and in oral nootropic supplements, neither of which is an approved use. |
| Half-life | Roughly 33 hours after oral dosing. Absorption is poor and highly dependent on fat co-ingestion, which is why dosing with a meal containing fat is the standard instruction. | Short in plasma, a matter of hours, with extensive first-pass metabolism to conjugated metabolites. |
| Molecular weight | 863.3 Da. Ubiquinol is the reduced form, 865.4 Da, marketed as better absorbed; head-to-head clinical outcome data comparing the two do not exist. | 338.4 Da |
| Mechanism | Coenzyme Q10 is an endogenous lipid-soluble electron carrier in the mitochondrial inner membrane, shuttling electrons from complexes I and II to complex III in the respiratory chain. In its reduced form, ubiquinol, it is also a lipid-phase antioxidant that regenerates vitamin E. Statins inhibit HMG-CoA reductase, which sits upstream of both cholesterol and CoQ10 synthesis in the mevalonate pathway, and that shared pathway is the mechanistic rationale for the statin myalgia hypothesis. The rationale is sound and the trials still came back null, which is a useful reminder that a coherent mechanism is not a result. | A short-chain benzoquinone that can accept electrons from cytosolic NAD(P)H quinone dehydrogenase 1 and deliver them to complex III, bypassing a defective complex I. That is a coherent rationale for a disease caused by complex I mutations, which is what Leber hereditary optic neuropathy is, and it is why the drug found its indication there rather than in general antioxidant use. The reduction step depends on NQO1: in NQO1-deficient cells idebenone has been reported to cause cell death rather than protect, so the mechanism is conditional on the tissue's enzyme status rather than being a generic antioxidant effect. |
| Human studies cited | 1 | 5 |
| Legal status, US | Sold as a supplement | Not approved; sold in cosmetics and supplements |
Frequently asked questions
What is the difference between CoQ10 and Idebenone?
CoQ10: One genuinely strong randomised outcome trial, in moderate to severe heart failure, where it cut major events from 26% to 15%. And a clean null for statin muscle pain, which is why most people take it. Idebenone: Authorised in the European Union for one rare mitochondrial optic neuropathy, granted under exceptional circumstances because the normal evidence standard was not met. The randomised trial that supported it missed its primary endpoint, and the trials in Alzheimer's disease and Friedreich ataxia were negative.
Which has stronger research evidence, CoQ10 or Idebenone?
This database does not grade compounds. It counts what was run in people: 1 of the 2 studies cited on the CoQ10 profile were human work, against 5 of 6 for Idebenone. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are CoQ10 and Idebenone FDA-approved?
CoQ10: Sold as a dietary supplement in the United States. Not approved to prevent or treat any condition. Approved as a drug in some other jurisdictions for specific cardiac indications.. Idebenone: Not FDA approved for any indication. Authorised in the European Union as Raxone for Leber hereditary optic neuropathy since September 2015, under exceptional circumstances. Separately sold in topical skincare and in oral nootropic supplements, neither of which is an approved use..
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.